Edgardo D. Carosella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Edgardo D. Carosella has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Masson-Lecomte
Saint-Louis Hospital 1 Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute Paris, France
8 shared publications - Alix Jacquier
Saint-Louis Hospital 1 Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute Paris, France
8 shared publications - Clément Dumont
Department of Medical Oncology, Hôpital Saint Louis, AP-HP, Paris, France
8 shared publications - Dzenis Koca
INSERM 4 Interdisciplinary Research Institute of Grenoble, IRIG-Biosanté, University Grenoble Alpes, CEA UMR 1292, Grenoble, France
8 shared publications - Emilie Artru
INSERM U1342, Saint-Louis Research Institute, Université Paris Cité, Paris, France
8 shared publications - Fatiha Bouhidel
Saint-Louis Hospital 5 Department of Pathology AP-HP.Nord - Université Paris Cité, Paris, France
8 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S3. Transcriptomic characterization of the CD8+ILT2+ T cell subset
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S3. Transcriptomic characterization of the CD8+ILT2+ T cell subset
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S2. Quantitative analysis of spectral flow cytometry clusters.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S2. Quantitative analysis of spectral flow cytometry clusters.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S5. CD8+ILT2+ T cells display TCR-independent cytotoxicity selectively toward NKG2D ligand-expressing target cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S5. CD8+ILT2+ T cells display TCR-independent cytotoxicity selectively toward NKG2D ligand-expressing target cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S4. CD8+ILT2− T cells do not exhibit TCR-independent cytotoxic potential.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S4. CD8+ILT2− T cells do not exhibit TCR-independent cytotoxic potential.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S1. Association of the HLA-G/ILT2 and PD-L1/PD1 checkpoints with clinical parameters in ccRCC.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Fig. S1. Association of the HLA-G/ILT2 and PD-L1/PD1 checkpoints with clinical parameters in ccRCC.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Immune checkpoint inhibitors (ICI) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G/ILT2 axis has emerged as a promising immunosuppressive pathway. In this study, we deeply characterized CD8+ILT2+ tumor-infiltrating lymphocytes (TIL) as a distinct subset from CD8+PD-1+ TILs in ccRCC, using high-dimensional spectral flow cytometry, single-cell transcriptomics, and T-cell receptor (TCR) clonotype analysis. CD8+ILT2+ TILs were terminally differentiated, highly cytotoxic “bystander” cells, enriched for virus-specific TCRs. They phenotypically, transcriptionally, and functionally mirrored their circulating counterparts, suggesting peripheral recruitment. In dynamic coculture assays, they exhibited potent TCR-independent cytotoxicity, mediated by activating innate receptors, namely NKG2D. However, HLA-G inhibited this activity, underscoring the immune-evasive role of the HLA-G/ILT2 axis. Our study defines CD8+ILT2+ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Immune checkpoint inhibitors (ICI) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G/ILT2 axis has emerged as a promising immunosuppressive pathway. In this study, we deeply characterized CD8+ILT2+ tumor-infiltrating lymphocytes (TIL) as a distinct subset from CD8+PD-1+ TILs in ccRCC, using high-dimensional spectral flow cytometry, single-cell transcriptomics, and T-cell receptor (TCR) clonotype analysis. CD8+ILT2+ TILs were terminally differentiated, highly cytotoxic “bystander” cells, enriched for virus-specific TCRs. They phenotypically, transcriptionally, and functionally mirrored their circulating counterparts, suggesting peripheral recruitment. In dynamic coculture assays, they exhibited potent TCR-independent cytotoxicity, mediated by activating innate receptors, namely NKG2D. However, HLA-G inhibited this activity, underscoring the immune-evasive role of the HLA-G/ILT2 axis. Our study defines CD8+ILT2+ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.
- 8 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (8) , OF1-OF16
ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Immune checkpoint inhibitors (ICI) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G/ILT2 axis has emerged as a promising immunosuppressive pathway. In this study, we deeply characterized CD8+ILT2+ tumor-infiltrating lymphocytes (TIL) as a distinct subset from CD8+PD-1+ TILs in ccRCC, using high-dimensional spectral flow cytometry, single-cell transcriptomics, and T-cell receptor (TCR) clonotype analysis. CD8+ILT2+ TILs were terminally differentiated, highly cytotoxic “bystander” cells, enriched for virus-specific TCRs. They phenotypically, transcriptionally, and functionally mirrored their circulating counterparts, suggesting peripheral recruitment. In dynamic coculture assays, they exhibited potent TCR-independent cytotoxicity, mediated by activating innate receptors, namely NKG2D. However, HLA-G inhibited this activity, underscoring the immune-evasive role of the HLA-G/ILT2 axis. Our study defines CD8+ILT2+ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.
- 8 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (8) , OF1-OF16
ILT2 Identifies an Unexploited Pool of Intratumoral CD8+ Bystander T Cells with TCR-Independent Cytotoxicity in Renal Cell Carcinoma
Immune checkpoint inhibitors (ICI) have improved clear-cell renal cell carcinoma (ccRCC) therapy, yet many patients remain unresponsive. Alternative strategies are needed, and the HLA-G/ILT2 axis has emerged as a promising immunosuppressive pathway. In this study, we deeply characterized CD8+ILT2+ tumor-infiltrating lymphocytes (TIL) as a distinct subset from CD8+PD-1+ TILs in ccRCC, using high-dimensional spectral flow cytometry, single-cell transcriptomics, and T-cell receptor (TCR) clonotype analysis. CD8+ILT2+ TILs were terminally differentiated, highly cytotoxic “bystander” cells, enriched for virus-specific TCRs. They phenotypically, transcriptionally, and functionally mirrored their circulating counterparts, suggesting peripheral recruitment. In dynamic coculture assays, they exhibited potent TCR-independent cytotoxicity, mediated by activating innate receptors, namely NKG2D. However, HLA-G inhibited this activity, underscoring the immune-evasive role of the HLA-G/ILT2 axis. Our study defines CD8+ILT2+ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.
- Open Access
CANNABIDIOL MODULATES CLASSICAL AND NON-CLASSICAL HLA EXPRESSION IN HUMAN CHORIOCARCINOMA CELL LINE
Cannabidiol (CBD) modulates diverse signaling pathways with potential relevance to tumor immune escape, however its impact on the regulation of classical and non-classical HLA class I molecules remains incompletely understood. Here, we examined the mechanisms by which CBD regulates HLA expression in JEG-3 choriocarcinoma cells, focusing on cannabinoid-related receptors and intracellular Ca²⁺ signaling. CBD increased the expression of classical HLA class I genes—most notably HLA-C—while reducing HLA-G levels, a non-classical HLA class I molecule that acts as a local immunosuppressor. Receptor profiling revealed constitutive expression of CB1 and CB2, whereas GPR55 and PPARγ expression became detectable only after CBD exposure. Functional inhibition assays showed that HLA-G downregulation was selectively attenuated by CB1 blockade, with no meaningful contribution from CB2 or GPR55. In contrast, CBD-induced HLA-C upregulation required GPR55 and CB2 activity, while being unaffected by CB1 inhibition, indicating distinct receptor pathways for classical and non-classical HLA regulation. Calcium chelation using BAPTA further demonstrated that HLA-G modulation is highly sensitive to intracellular Ca²⁺ reduction, whereas classical HLA expression required higher BAPTA concentrations to be affected. Altogether, these findings identify CBD as a dual immunomodulatory agent capable of enhancing tumor immune visibility while limiting immunotolerant HLA-G expression through receptor-specific and Ca²⁺-dependent mechanisms.
Open AccessCANNABIDIOL MODULATES CLASSICAL AND NON-CLASSICAL HLA EXPRESSION IN HUMAN CHORIOCARCINOMA CELL LINE
Cannabidiol (CBD) modulates diverse signaling pathways with potential relevance to tumor immune escape, however its impact on the regulation of classical and non-classical HLA class I molecules remains incompletely understood. Here, we examined the mechanisms by which CBD regulates HLA expression in JEG-3 choriocarcinoma cells, focusing on cannabinoid-related receptors and intracellular Ca²⁺ signaling. CBD increased the expression of classical HLA class I genes—most notably HLA-C—while reducing HLA-G levels, a non-classical HLA class I molecule that acts as a local immunosuppressor. Receptor profiling revealed constitutive expression of CB1 and CB2, whereas GPR55 and PPARγ expression became detectable only after CBD exposure. Functional inhibition assays showed that HLA-G downregulation was selectively attenuated by CB1 blockade, with no meaningful contribution from CB2 or GPR55. In contrast, CBD-induced HLA-C upregulation required GPR55 and CB2 activity, while being unaffected by CB1 inhibition, indicating distinct receptor pathways for classical and non-classical HLA regulation. Calcium chelation using BAPTA further demonstrated that HLA-G modulation is highly sensitive to intracellular Ca²⁺ reduction, whereas classical HLA expression required higher BAPTA concentrations to be affected. Altogether, these findings identify CBD as a dual immunomodulatory agent capable of enhancing tumor immune visibility while limiting immunotolerant HLA-G expression through receptor-specific and Ca²⁺-dependent mechanisms.